Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Maki Komiyama , Koji Hasegawa Added: 3 years ago
Type 2 diabetes is a major risk factor for the development of cardiovascular disease (CVD) such as MI, and cerebrovascular incidents such as stroke. A substantial body of evidence has indicated that the proper management of blood glucose in people with diabetes can inhibit the progression of microvascular disease such as retinopathy and nephropathy. Nevertheless, whether strict blood glucose… View more

Prevention & Chronic Conditions
Author(s): Domenic A Sica Added: 3 years ago
Introduction Diabetes mellitus is rapidly increasing in its worldwide prevalence and is currently estimated to affect 7-8% of the US population.1 In 2005, 1.5 million new cases of diabetes were diagnosed in people aged 20 years or older in the US. In the not-so- distant past, type-2 diabetes mellitus was viewed as a seemingly benign condition, at least in the elderly, with little effect on life… View more

Prevention & Chronic Conditions
The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Author(s): Sotirios Tsalamandris , Alexios S Antonopoulos , Evangelos Oikonomou , et al Added: 3 years ago
Diabetes is a multifaceted metabolic disorder affecting the glucose status of the human body. Impaired glucose tolerance and hyperglycaemia are the main clinical and diagnostic features and the result of an absolute or relative insulin deficiency or resistance to its action. Chronic hyperglycaemia associated with diabetes can result in end organ dysfunction and failure which can involve the… View more

Prevention & Chronic Conditions
Chelation Therapy in Post-MI Pts with Diabetes: TACT2
Author(s): Gervasio L Lamas Added: 1 week ago
ACC 24 - In this video, Dr Gervasio L Lamas (Mount Sinai Medical Center, US) joins us onsite to discuss the findings from the TACT2 study of chelation therapy in post-myocardial infarction patients with diabetes (NCT02733185).The Trial to Assess Chelation Therapy 2 (TACT2) study is a randomized, double blind factorial clinical trial, aiming to determine if chelation-based strategy increases the… View more

Prevention & Chronic Conditions

MI/ACS
VOYAGER PAD: Rivaroxaban in Symptomatic PAD With & Without Comorbid Diabete
Author(s): Cecilia Low Wang Added: 2 years ago
Dr Cecilia Low Wang (Colorado Prevention Center, US) discusses the findings from the VOYAGER PAD - rivaroxaban in symptomatic PAD with and without comorbid diabetes study. The study assessed the efficacy and safety of rivaroxaban in patients with PAD with concomitant diabetes after lower extremity revascularization. The study presented at ESC Congress 2021 showed that the efficacy of rivaroxaban… View more

Vascular Disease and Surgery

Intervention
Author(s): Su Down Added: 3 years ago
This programme has been created with a view to educate primary care healthcare professionals in the UK to understand when, and for whom, they should prescribe SGLT2 inhibitors and to understand the latest advancements in this drug class. Boehringer Ingelheim Ltd has supported this event as a Medical Education Grant and has had no other involvement in the organisation or the delivery of… View more

Heart Failure

Prevention & Chronic Conditions
EASD 22: SURMOUNT-MMO: Tirepatide in Obese Type II Diabetes Patients
Author(s): Steven E Nissen Added: 1 year ago
EASD 22 - Dr Steven Nissen (Cleveland Clinic, US) joins us to discuss the findings of the SURMOUNT-MMO trial. This study aimed to evaluate the effect of tirzepatide in type II diabetes patients who have obesity, or are overweight. Questions: 1. What was the rationale behind this study? 2. What is the mechanism of action of Tirzepatide? 3. What was the study design? 4. What were the main outcomes… View more

Prevention & Chronic Conditions
EASD 23: Epidemiologic Trends & Disparities in Diabetes Risk Among LGBTQ+ Population
Author(s): Carl Streed Added: 6 months ago
EASD 2023 – Dr Carl G Streed (Boston University School of Medicine, US) joins us to summarise healthcare disparities among the LGBTQ+ population.In this interview, Dr Streed discusses the available evidence and explains the minority stress model. This model suggests that experiences of discrimination and stress contribute to worse health outcomes in the LGBTQ community. This can lead to mental… View more

Demographic

Prevention & Chronic Conditions
ACC.24: The STEP HFpEF DM Trial
Author(s): Mikhail Kosiborod Added: 1 week ago
ACC.24 — We are joined onsite by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss the findings from the STEP HFpEF DM Trial (NCT04916470).The STEP HFpEF DM study aimed to investigate the effect of taking semaglutide 2.4mg once weekly in patients with heart failure with preserved ejection fraction (HFpEF) and diabetes mellitus type 2. The study looked at the impact of… View more

Heart Failure

Prevention & Chronic Conditions
Author(s): Lars Rydén , Linda Mellbin , Klas Malmberg Added: 3 years ago
The worldwide prevalence of diabetes in 2010 is already at epidemic proportions with an estimated 284.6 million adults (aged 20–79 years), representing 6.4% of the global adult population.1 However, more worryingly, the prevalence has increased by 15% since 20072 and projections estimate that 438.4 million adults will have diabetes in 2030, a 54% increase on 2010 figures.1 This drastic rise in… View more

Prevention & Chronic Conditions